Ovoca Bio announces that the Company will be attending the 25th annual BIO-Europe Partnering Conference, taking place from 11-13 November 2019, in Hamburg, Germany.
Ovoca Bio plc is pleased to announce that on 2nd September 2019 its subsidiary, IVIX, received patent No 6552960 in Japan covering pharmaceutical use for a list of peptide variants based on BP-101.
The 37th BIO International Convention in Philadelphia, United States.
Ovoca Presents at BIO 2019 International Convention, Philadelphia
Ovoca Bio plc is pleased to announce that on 1st March 2019 its subsidiary, IVIX, was granted patent No 234753 in Israel covering any use for a large list of peptide variants based on BP-101.
Ovoca Bio plc is pleased to announce that its subsidiary IVIX has commenced the process of preparing an integrated Clinical Development Plan (“CDP”) for its investigational drug candidate, Libicore (BP-101), for both the US and EU regions with Biorasi LLC (“Biorasi”), an experienced US-based contract research organization.
Ovoca Presents at BIO-Europe Spring® 2019, Vienna
Ovoca is pleased to announce that IVIX has signed an agreement with Biopharma Excellence GmbH (Germany), an experienced biopharmaceutical drug development consultancy firm, to provide regulatory affairs services.
Ovoca is pleased to announce that on 25th of September 2018 the notary public notified the Company that its subsidiary, Silver Star Ltd., has been formally registered on the Russian Unified State Register of Legal Entities as the owner of ...
On 27th of July 2018, Ovoca Gold Plc held Annual General Meeting and Extraordinary General Meeting in Radisson Blu St Helen hotel in Dublin, as it was announced on 4th of July 2018.